0

A review of consistencies in decision-making across NICE health technology assessments of immune heckpoint inhibitors

Authors:

Hale O, Casson J, Horscroft J, Sullivan W and Kiff C.

Publication type:

Conference Proceedings – Poster

Publication Name:

Virtual ISPOR Europe 2020

Citation:

Hale O, Casson J, Horscroft J, Sullivan W and Kiff C. A review of consistencies in decision-making across NICE health technology assessments of immune heckpoint inhibitors. Virtual ISPOR Europe 2020. 16-19 November 2020. Poster PCN249.

Link to publication ⟶

⟵ Back to Search Results

Cost-effectiveness analysis of NOVEL therapies for HER2+ metastatic breast cancer- [FAM-] trastuzumab deruxtecan versus tucatinib trastuzumab and capecitabine
Matching-adjusted indirect treatment comparisons of the effect of lorlatinib versus chemotherapy on overall survival and progression-free survival for patients with second-line or later anaplastic lymphoma kinase-positive advanced non-small cell lung cancer
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies